JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Price, Forecast & Analysis
NASDAQ:JAZZ • IE00B4Q5ZN47
JAZZ Key Statistics, Chart & Performance
The current stock price of JAZZ is 167.515 USD. In the past month the price decreased by -2.83%. In the past year, price increased by 24.15%.
JAZZ Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to JAZZ. When comparing the yearly performance of all stocks, JAZZ is one of the better performing stocks in the market, outperforming 80.23% of all stocks.
JAZZ Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ. There are concerns on the financial health of JAZZ while its profitability can be described as average.
JAZZ Financial Highlights
Over the last trailing twelve months JAZZ reported a non-GAAP Earnings per Share(EPS) of 8.16. The EPS decreased by -58.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| Debt/Equity | 1.09 |
JAZZ Forecast & Estimates
23 analysts have analysed JAZZ and the average price target is 221.83 USD. This implies a price increase of 32.43% is expected in the next year compared to the current price of 167.515.
For the next year, analysts expect an EPS growth of -60.74% and a revenue growth 4.8% for JAZZ
JAZZ Ownership
JAZZ Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.03 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.91 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.51 | 301.342B | ||
| PFE | PFIZER INC | 9.13 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.9 | 123.651B | ||
| ZTS | ZOETIS INC | 18.53 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.79 | 26.086B | ||
| VTRS | VIATRIS INC | 6.21 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.91 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.5 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JAZZ
Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Company Info
JAZZ PHARMACEUTICALS PLC
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4
DUBLIN DUBLIN D04 IE
CEO: Bruce C. Cozadd
Employees: 2800
Phone: 35316347800
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you describe the business of JAZZ PHARMACEUTICALS PLC?
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Can you provide the latest stock price for JAZZ PHARMACEUTICALS PLC?
The current stock price of JAZZ is 167.515 USD. The price increased by 0.72% in the last trading session.
What is the dividend status of JAZZ PHARMACEUTICALS PLC?
JAZZ does not pay a dividend.
How is the ChartMill rating for JAZZ PHARMACEUTICALS PLC?
JAZZ has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists JAZZ stock?
JAZZ stock is listed on the Nasdaq exchange.
How is the valuation of JAZZ PHARMACEUTICALS PLC (JAZZ) based on its PE ratio?
The PE ratio for JAZZ PHARMACEUTICALS PLC (JAZZ) is 20.53. This is based on the reported non-GAAP earnings per share of 8.16 and the current share price of 167.515 USD.
Should I buy JAZZ stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on JAZZ.